KOLOA, Hawaii — Patients with thyroid eye disease treated with teprotumumab demonstrated a significant reduction in proptosis compared with those treated with placebo, according to phase 3 results from the OPTIC trial.
The ideal treatment for thyroid eye disease would decrease inflammation, reduce proptosis and double vision, improve quality of life, have minimal adverse effects and minimize the need for surgical treatment, Raymond S. Douglas, MD, PhD, director of the orbital and thyroid eye disease program at Cedars-Sinai Medical Center, said in a presentation on the topic at Hawaiian
Uncategorized